Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model
Dow Jones Industrial Average
) is trading up 111 points (+0.8%) at 14,871 as of Wednesday, Jun 26, 2013, 12:35 p.m. ET. During this time, 248.8 million shares of the 30 Dow components have changed hands vs. an average daily trading volume of 621.9 million. The NYSE advances/declines ratio sits at 2,309 issues advancing vs. 677 declining with 72 unchanged.
- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
The Dow component leading the way higher looks to be
), which is sporting a $1.22 gain (+1.4%) bringing the stock to $86.58. This single gain is lifting the Dow Jones Industrial Average by 9.23 points or roughly accounting for 8.3% of the Dow's overall gain. Volume for Johnson & Johnson currently sits at 5.1 million shares traded vs. an average daily trading volume of 10.1 million shares.
Johnson & Johnson has a market cap of $237.66 billion and is part of the health care sector and drugs industry. Shares are up 21.8% year to date as of Tuesday's close. The stock's dividend yield sits at 3.1%.
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. The company has a P/E ratio of 23.1, above the S&P 500 P/E ratio of 17.7.
TheStreet Ratings rates Johnson & Johnson as a
. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income.
- You can view the full Johnson & Johnson Ratings Report.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.